← 홈

Antibody

1,230개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,230개
AntibodystaleKite, A Gilead CompanyPhase 1

Lenzilumab (Lenzilumab)

Relapsed/Refractory Large B-cell Lymphoma · FRα

#FR#Antibody#Phase1#항체#면역항체+4
효능 ORR 9.9%임상시험 6상태 DISCONTINUED
AntibodystaleThe Affiliated Nanjing Drum Tow…Phase 2

Triplizumab (Triplizumab)

Bladder Cancer · Bladder Cancer

#BladderCancer#Antibody#Phase2#항체#면역항체+2
임상시험 6상태 ACTIVE
AntibodystaleJuno Therapeutics, Inc., a Bris…Phase 3

Alnuctamab (Alnuctamab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#항체#면역항체+2
임상시험 5상태 DISCONTINUED
AntibodystaleAravive, Inc.Phase 2

Batiraxcept (Batiraxcept)

Clear Cell Renal Cell Carcinoma · Clear Cell Renal Cell Carcinoma

#ClearCellRenalCellCarcinoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 11%임상시험 5상태 DISCONTINUED
AntibodystaleMerck Sharp & Dohme LLCPhase 2

Boserolimab (Boserolimab)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#항체#면역항체+4
효능 ORR 7.1%임상시험 5상태 RECRUITING
AntibodystaleNovartisPhase 3

Investigational Arm - secukinumab (Investigational Arm - secukinumab)

Plaque Psoriasis; Non-alcoholic Fatty Liver Disease · Plaque Psoriasis

#PlaquePsoriasis#Antibody#Phase3#항체#면역항체+3
임상시험 5상태 DISCONTINUED
AntibodystaleXencor, Inc.Phase 2

Vudalimab (Vudalimab)

Ovarian Cancer; Clear Cell Carcinoma · Castration-Sensitive Prostate Carcinoma

#Castration-SensitiveProstateCarc#Antibody#Phase2#항체#면역항체+4
임상시험 5상태 DISCONTINUED
AntibodystaleSeagen Inc.Phase 2

vadastuximab talirine (vadastuximab talirine)

Myelodysplastic Syndrome · Myelodysplastic Syndrome

#MyelodysplasticSyndrome#Antibody#Phase2#항체#면역항체+2
임상시험 5상태 DISCONTINUED
AntibodystaleActinium PharmaceuticalsPhase 1

131-I Apamistamab (131-I Apamistamab)

B-ALL; DLBCL · B-ALL

#B-ALL#Antibody#Phase1#항체#면역항체+3
임상시험 4상태 RECRUITING
AntibodystaleRochePhase 2

131I-rituximab (131I-rituximab)

Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 4상태 ACTIVE
AntibodystaleUniversity of CalgaryApproved

ustekinumab (Stelara, Anti-IL12/23 or anti-IL23 - Ustekinumab)

Crohn Disease · Crohn Disease

#CrohnDisease#Antibody#Approved#항체#면역항체+2
임상시험 4상태 RECRUITING
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab [TECENTRIQ])

Neoplasms · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 33.33%임상시험 4상태 ACTIVE
AntibodystaleEisai Inc.Phase 2

Farletuzumab ecteribulin (Farletuzumab ecteribulin)

Solid Tumor · Solid Tumor

#SolidTumor#Antibody#Phase2#항체#면역항체+2
효능 ORR 20%임상시험 4상태 RECRUITING
AntibodystaleEli Lilly and CompanyPhase 2

Icrucumab (Icrucumab)

Colon Cancer; Rectal Cancer · Carcinoma of Urinary Tract

#CarcinomaofUrinaryTract#Antibody#Phase2#항체#면역항체+4
효능 ORR 28.8%임상시험 4상태 ACTIVE
AntibodystaleAstraZenecaPhase 3

MEDI4736+Tremelimumab (MEDI4736+Tremelimumab)

Squamous Cell Carcinoma of the Head and Neck · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#Antibody#Phase3#항체#면역항체+2
효능 ORR 37.4%임상시험 4상태 ACTIVE
AntibodystaleBiogenPhase 2

Natalizumab (Natalizumab)

Crohn's Disease · Multiple Sclerosis, Relapsing-Remitting

#MultipleSclerosisRelapsing-Remit#Antibody#Phase2#항체#면역항체+3
효능 ORR 52%임상시험 4상태 ACTIVE
AntibodystaleHoffmann-La RochePhase 2

Rituxumab (Rituxumab)

B-cell Non-Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma

#B-cellNon-HodgkinLymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 95%임상시험 4상태 ACTIVE
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, SD-101 + Pembrolizumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 3.2%임상시험 4상태 RECRUITING
AntibodystaleBeiGenePhase 1

atezolizumab (Tecentriq, Tislelizumab，atezolizumab or sugemalimab)

NSCLC · NSCLC

#NSCLC#Antibody#Phase1#항체#면역항체+2
임상시험 4상태 RECRUITING
AntibodystaleRegeneronPhase 2

VV1 + Cemiplimab (VV1 + Cemiplimab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 4상태 RECRUITING

12 / 62 페이지

← 이전다음 →